Monopar Therapeutics (MNPR) Appoints Octávio Costa, MD, as Chief Medical Officer

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar’s pipeline.

Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clinical development expertise as well as regulatory experience. Dr. Costa’s previous roles include positions of increasing responsibility in clinical development at Merck, Celgene, Novartis and most recently as Chief Medical Officer at Rafael Pharmaceuticals. He has played an important role in the development and life-cycle management of significant products, including the blockbuster product REVLIMID® (lenalidomide). Dr. Costa earned his Doctor of Medicine from The Medical College of Sorocaba, São Paulo.

“We are excited to welcome Octávio, especially as our lead program enters late-stage clinical studies,” said Chandler Robinson, MD, Chief Executive Officer of Monopar. “Octávio’s track record of navigating all stages of clinical development will aid Monopar in executing our growing clinical development pipeline.”

“I am thrilled to be joining this accomplished management team, as Monopar’s Chief Medical Officer,” said Dr. Costa. “My industry knowledge and expertise in moving cancer therapies through all stages of clinical testing is well suited to help accelerate Monopar’s pipeline of innovative mid- and late-stage clinical programs and early drug development candidates.”

You May Also Be Interested In

• WD-40 names Keith Stauffer as incoming CFO
• Real Matters CFO Rodrigo Pinto to step down in November
• MediaAlpha names new CFO and raises Q3 2026 guidance